Suliqua-logo

Profile

At week 30, Suliqua® significantly reduced HbA1c by 1.6% in a pivotal trial1-2

Suliqua® reduced HbA1c by 2.9% in a post hoc supgroup analysis of patients with HbA1c of >9%3

Suliqua® is a favourable alternative to premixed insulins when intensifying from metformin + basal insulin + OADs4

Supporting people with Type 2 diabetes that are prescribed Suliqua - two pens available

    1. SULIQUA® SmPC as of May 2021.
    2. Rosenstock J, Aronson R, Grunberger G, et  al. Diabetes Care. 2016;39:2026-2035.
    3. Davies MJ, Russell-Jones D, Barber TM, et al. Diabetes Obes Metab. 2019:21:1967-1972.
    4. Rosentock J, Emral R, Sauque-Reyna L, et al. Diabetes Care. 2021:dc210393;D0I: 10.2337/dc-21-0393.

Usage

Download guides about dosing and titration of Suliqua and more information on risk minimisation. 

Suliqua Guide 100/33 Dosing and Titration Guide

Suliqua Guide 100/50 Dosing and Titration Guide

RISK MINIMISATION

Important information on dosing to help reduce the risk of any medical error

Diabetes Stories

Watch and listen to your peers discussing rapid-acting biosimilars and their best practices while using them.

Post GLP-1 Therapy

Length: 6:47

Nurse Grace Vanterpool gives an overview of how to use Suliqua in patients post GLP-1 therapy.

Post Insulin Therapy

Length: 6:36

Nurse Grace Vanterpool gives an overview of how to use Suliqua in patients requiring intensification of a basal insulin regimen.

Post Oral Therapy

Length: 6:45
 

Nurse Grace Vanterpool gives an overview of how to use Suliqua in insulin naïve patients.

Using Suliqua in Clinical Practice

Length: 16:20

Dr Amar Ali gives a brief overview of Suliqua®, including how to choose the appropriate Suliqua pen when prescribing in clinical practice and illustrates his experience with a case study. 

Get in touch with the Diabetes Team

MAT-XU-2201545 (v1.0)
Date of Preparation: June 2022

MAT-GB-2105438 (v1.0)
Date of Preparation: June 2022